Dr Jeremy de Leon
/content/dam/asset-migration/headshots/au-doctor-headshots/AU_Oncology_Headshot_Dr_Jeremy_De_Leon.jpg

Dr Jeremy De Leon

Dr Jeremy De Leon
Jeremy
De Leon
BSc (Bioinformatics), M.B.B.S (Honours), FRANZCR, Radiation Oncologist

Languages spoken

English

Overview

Clinical interests in upper gastrointestinal (GI), urogenital and lung cancers.

Jeremy completed a Bachelor of Science in Bioinformatics prior to graduating from a Bachelor of Medicine with Honours in 2006 from the University of Sydney. He completed his radiation oncology training at Liverpool, Campbelltown and Canberra Hospitals, followed by a Fellowship at the Royal North Shore Hospital.

Jeremy subsequently took up a staff specialist position at the Illawarra and Shoalhaven Cancer Therapy Centres, prior to joining GenesisCare, St Vincent's in Sydney, as a key member of the MRIgRT clinical team.

Jeremy's clinical interests are upper GI, urogenital and lung cancers. Jeremy has experience using the MRIgRT technology to treat different tumour types.

Jeremy is an active clinician researcher and investigator in international and national clinical trials. He has also collaborated with the University of Wollongong on PBMC signatures following radiotherapy and has authored multiple publications in peer-reviewed journals.

He has an interest in modern treatment techniques to improve patient outcomes, and is a member of the MRIgRT team at GenesisCare, St Vincent's in Sydney.

Outside of work, Jeremy enjoys time with his family, which usually revolved around food.

Research interests

  • Radiation therapy technologies including MRIgRT, stereotactic radiation therapy, and biomarkers.

Professional memberships

  • FRANZCR
  • ANZUP
  • FROLIC
  • Breast Cancers Trial Group
  • AGITG
  • ALTG

Publications

  • de Leon J, Jameson MG, Rivest-Henault D, Keats S, Rai R, Arumugam S, Wilton L, Ngo D, Liney G, Moses D, Dowling J, Martin J, Sidhom M Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy. Br J Radiol. 2019 Jun;92(1098)
  • de Leon J, Kneebone A, Gebski V, Cross S, Do V, Hayden A, Ngo D, Sidhom M, Turner S. Long-term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy. J Med Imaging Radiat Oncol. 2019 Feb;63(1):116-123
  • de Leon J, Jameson MG, Windsor AA, Cloak K, Keats S, Vial P, Holloway L, Metcalfe P & Sidhom M: Superior target volume and organ stability with the use of Endorectal Balloons in Post Prostatectomy Radiotherapy. J Med Imaging Radiat Oncol. 2015 Aug;59(4):507-13.
  • Jameson MG, de Leon J, Windsor AA, Cloak K, Keats S, Dowling JA, Chandra SS, Vial P, Sidhom M, Holloway L & Metcalfe P. Endorectal balloons in the post prostatectomy setting: do gains in stability lead to more predictable dosimetry? Radiother Oncol. 2013 Dec;109(3):493-7
  • Roach D, Holloway LC, Jameson MG, Dowling JA, Kennedy A, Greer PB, Krawiec M, Rai R, Denham J, de Leon J, Lim K, Berry ME, White RT, Bydder SA, Tan HT, Croker JD, McGrath A, Matthews J, Smeenk RJ, Ebert MA. Multi-observer contouring of male pelvic anatomy: Highly variable agreement across conventional and emerging structures of interest. J Med Imaging Radiat Oncol. 2019 Apr;63(2):264-271